Background
==========

Ovarian brosarcomas primarily originate in the ovaries \[[@B1]\], and are very rare tumors. Correspondingly, very few cases of ovarian fibrosarcoma have been reported. As a result, ovarian fibrosarcomas can be difficult to distinguish clinically and histologically from cellular fibromas \[[@B1]-[@B3]\]. The malignant potential of ovarian fibrosarcomas are usually assessed based on observed growth patterns, cellular atypia, and mitotic counts \[[@B2]\]. However, due to the low incidence of this disease, it is difficult to enroll a sufficient number of patients to evaluate the prognostic factors associated with survival. Furthermore, since an optimal treatment strategy for this aggressive tumor has not yet been identified, it is not only difficult to treat patients with ovarian fibrosarcoma, but most patients with this disease do not survive more than 2 years due to early metastasis via the bloodstream and tumor recurrence \[[@B4]\]. As a result, the prognosis for patients with fibrosarcoma is very poor \[[@B1],[@B2],[@B5]\], and there are few reports regarding the long-term survival of patients with ovarian fibrosarcoma.

Therefore, in this study, a retrospective multi-center clinical trial was established to determine whether clinical or pathologic prognostic factors can be identified for patients with ovarian fibrosarcoma.

Methods
=======

A total of 31 patients diagnosed with ovarian fibrosarcoma were identified from various sources. Three of these cases were treated at the First Affiliated Hospital, Medical College of Shantou University (Guang Dong, China) and 5 cases were treated at the Cancer Center, Sun Yat-sen University (Guang Dong, China). In addition, 5 case reports published in a Chinese journal \[[@B6]-[@B10]\], and 18 cases reported in the PubMed database between January 1995 and December 2009 were retrospectively examined. Institutional review board approval was obtained from each of the participating centers.

Histopathologic diagnosis was based on morphologic criteria and immunohistochemical staining. Patients from the Medical College of Shantou University (n = 3) and the Cancer Center, Sun Yat-sen University (n = 5) were staged according to the FIGO clinical staging system for ovarian cancer, and included information from physical examinations, chest X-rays, intravenous (i.v.) pyelography, cystoscopy, sigmoidoscopy, abdomino-pelvic computed tomography (CT) scans, or magnetic resonance imaging (MRI). When suspicious findings were identified on chest X-rays and/or during physical examination, a CT scan of the chest and/or brain was performed.

Clinical and pathological variables analyzed included patient age, tumor size, FIGO stage, symptoms, mitotic events, immunohistochemical results, and treatment modalities. The primary end point was any cancer-related death. End points were calculated from the date of surgery for the cases from the Medical College of Shantou University and the Cancer Center, Sun Yat-sen University, while a presumed date of surgery was estimated for the additional 23 cases reviewed from the literature.

Overall survival (OS) and disease-free survival (DFS) were evaluated using the Kaplan-Meier method and log-rank tests. The Cox proportional hazards model was used to estimate the independent factors prognostic for OS and DFS. All analyses were carried out using SPSS software (version 13.0, SPSS Inc., Chicago, IL), and a significance level of 0.05 was used. All end points were updated in March 2010.

Results
=======

Clinical Features
-----------------

In this cohort (n = 31), patient age ranged from 20 - 73 years, with a median age of 49 years (Table [1](#T1){ref-type="table"}). For 6/25 (24%) patients, the ovarian fibrosarcomas were detected during a routine gynecological examination. Alternatively, 19/25 (76%) patients presented with abdominal pain, vaginal bleeding, or notable pelvic swelling at a hospital. For 6/31 cases that were reviewed from published case reports, the details of presentation were not provided \[[@B2]\]. FIGO staging of the tumors of this cohort included 15 (49%) stage I cases, 6 (19%) stage II cases, 9 (29%) stage III cases, and 1 (3%) stage IV case. Correspondingly, treatment for this cohort varied. Nine patients were treated with a total hysterectomy with bilateral adnexectomy and an omentectomy (BAO), 8 patients underwent an oophorectomy (OR), 1 patient received chemotherapy (CT), 11 patients received BAO followed by a chemotherapy (BAO+CT), and 2 patients underwent BAO followed by treatment with radiotherapy (BAO+RT). After a median follow-up period of 14 months (range, 2-120), the 2-year OS rates and 2-year DFS rates for this cohort were 55.9% and 45.4%, respectively (Figure [1A](#F1){ref-type="fig"}).

###### 

The clinical and pathologic features of the ovarian fibrosarcoma cases examined

  Reference                      Case No.   Age   Symptom   FIGO stage   Largest diameter (cm)   Mitoses/10 HPFs   CD10   Ki-67 (MIB-1) positive   Vimentin   CD117   SMA   Des   EMA   S-100   CD99   CD34   α-inhibin   ER    PR    CA125 U/ml   Therapy         Recurrence   Follow-up (months)           
  ------------------------------ ---------- ----- --------- ------------ ----------------------- ----------------- ------ ------------------------ ---------- ------- ----- ----- ----- ------- ------ ------ ----------- ----- ----- ------------ --------------- ------------ -------------------- ------- -----------------------
  China Case 1\[[@B6]\]          1          43    AP        III c        10                      ≥ 4               (-)    50%-75%                  (+)        (-)     (-)   /     /     (-)     (-)    /      (-)         (-)   (-)   /            OR              1            Pelvis               BAO     Died (4)
  China Case 2 \[[@B7]\]         2          39    AP        I a          11                      5\~7              (-)    85%                      (+)        /       (-)   (-)   (-)   (-)     (-)    /      (-)         (-)   (-)   /            BAO             NP           NP                   NP      TF (14)
  China Case 3                   3          53    NP        I a          10                      3\~7              /      /                        (+)        /       (-)   (-)   (-)   (-)     (-)    /      (-)         (-)   (-)   68.45        BAO             NP           NP                   NP      TF (12)
  China Case 4                   4          20    NP        II a         7                       3\~5              /      15%                      (+)        (-)     (-)   (-)   (-)   (-)     (-)    /      (-)         /     /     /            BAO             6            Pelvis               CT      Died (10)
  China Case 5\[[@B8]\]          5          56    NP        III c        16                      13                (-)    25%                      (+)        (-)     (-)   (-)   (-)   (-)     (-)    (-)    /           /     /     \< 35        BAO+(IA+DTIC)   NP           NP                   NP      TF (8)
  China Case 6\[[@B9]\]          6          43    NP        I a          5.7                     16                (-)    \> 10%                   (+)        /       (-)   /     /     (-)     /      (-)    (+)         /     /     \< 35        BAO+PVB         NP           NP                   NP      TF (7)
  China Case 7 \[[@B10]\]        7          21    AP        III b        15                      ≥ 4               /      \> 10%                   (+)        /       /     /     /     /       /      /      /           /     /     /            OR              3            Pelvis               NP      Died (6)
  China Case 8                   8          66    AP        II b         11                      8                 /      15%                      (+)        /       (-)   (-)   (-)   (-)     /      /      (-)         /     /     /            BAO             10           Sigmoid              SS+CT   Died (23)
  China Case 9                   9          37    AP        II c         /                       ≥ 4               (+)    20%                      (+)        (-)     (-)   (-)   (-)   (-)     /      (-)    (-)         (-)   (-)   198          BAO+(IA+DTIC)   NP           NP                   NP      TF (15)
  China Case 10                  10         44    AP        III b        13                      23                (-)    75%                      (+)        /       (-)   /     /     (-)     /      /      (-)         /     /     /            OR              1            Pelvis               NP      Died (3)
  China Case 11                  11         52    AP        II b         12                      14                /      \< 5%                    /          /       /     /     /     /       /      /      /           /     /     /            BAO+IAP         16           Pelvis               CT      Alive with tumor (34)
  China Case 12                  12         48    NP        I a          8                       3\~4              (-)    \< 5%                    (+)        /       (-)   (-)   /     (-)     /      /      (-)         /     /     /            BAO+IAP         NP           NP                   NP      TF (45)
  China Case 13                  13         61    AP        III b        15                      18                /      60%                      (+)        /       (+)   (-)   (-)   (-)     /      /      (+)         /     /     /            OR              2            Pelvis               NP      Died (11)
  Lee et al. \[[@B17]\]          14         69    VB        I            6                       6\~8              /      \> 10%                   /          /       /     /     /     /       /      /      (+)         /     /     /            BAO             /            /                    /       /
  Kruger et al. \[[@B18]\]       15         32    NP        I            7                       8                 /      5%-10%                   /          /       /     (-)   (-)   (-)     /      (-)    /           /     /     116.1        OR              NP           NP                   NP      TF (12)
  Choi et al. \[[@B19]\]         16         44    AP        I a          18                      17                /      \< 1%                    (+)        /       (-)   /     /     (-)     /      /      /           (-)   (-)   /            BAO+AP          NP           NP                   NP      TF (120)
                                 17         34    AP        I b          13                      8                 /      20%                      (+)        /       (-)   /     /     (-)     /      /      /           (+)   (+)   26.5         BAO+(VP16+IP)   NP           NP                   NP      TF (60)
  Testa et al. \[[@B20]\]        18         44    NP        III b        /                       7                 /                               (+)        /       /     /     /     /       /      /      (+)         /     /     /            BAO+IA          NP           NP                   NP      TF (50)
                                 19         50    NP        I a          /                       5\~7              /      12%                      (+)        /       /     /     /     /       /      /      (+)         /     /     /            BAO             NP           NP                   NP      TF (5)
  Jimenez et al. \[[@B21]\]      20         55    VB        I c          23                      \< 1-2            /      60%                      (+)        (-)     (-)   /     /     /       /      /      /           /     /     /            BAO+IA          14           Liver                SS      Alive with tumor (14)
  Celyk et al. \[[@B5]\]         21         49    AP        III c        12                      ≥ 4               /      ?                        (+)        /       /     (+)   /     (+)     /      /      /           /     /     300          BAO+TP          36           Pelvis, liver        NP      Died (42)
  McCluggage et al. \[[@B22]\]   22         61    AP        III c        7                       12\~15            /      /                        (+)        /       (-)   (-)   /     (-)     /      /      (+)         /     /     196          BAO+CT          /            /                    /       /
  Prat et al. \[[@B2]\]          23         61    /         I a          10                      4                 /      /                        /          /       /     /     /     /       /      /      /           /     /     /            BAO+RT          18           Liver                NP      Died (18)
                                 24         59    /         II b         /                       8                 /      /                        /          /       /     /     /     /       /      /      /           /     /     /            BAO             1            Sigmoid              SS+RT   Died (4)
                                 25         42    /         II b         /                       25                /      /                        /          /       /     /     /     /       /      /      /           /     /     /            BAO             1            Ureter               RT      Alive with tumor (13)
                                 26         65    /         I a          /                       10                /      /                        /          /       /     /     /     /       /      /      /           /     /     /            OR              6            Pelvis               NP      Died (13)
                                 27         73    /         III          6                       7                 /      /                        /          /       /     /     /     /       /      /      /           /     /     /            CT              2            Pelvis, Peritoneum   CT      Died (2)
                                 28         49    /         I a          /                       5                 /      /                        /          /       /     /     /     /       /      /      /           /     /     /            BAO             44           Pelvis, Peritoneum   CT      Died (48)
  Fukuda et al. \[[@B23]\]       29         54    AP        I a          22                      3\~6              /      5.4%-8.2%                (+)        /       (-)   (-)   (-)   (-)     /      (+)    (+)         /     /     /            OR              14           Pelvis               SS+AP   TF (22)
  Iiboshi et al. \[[@B24]\]      30         38    NP        I a          5.2                     20\~25            /      /                        (+)        /       (-)   /     (-)   (-)     /      /      /           /     /     /            OR              NP           NP                   NP      TF (24)
  Watanabe et al. \[[@B25]\]     31         44    NP        IV           12                      \< 4              /      /                        (+)        /       (+)   (-)   (-)   (-)     (-)    /      /           /     /     /            OR+RT           /            /                    /       Died (4)

**NP**, not performed; TF, tumor-free; **AP**(Symptom), abdominal pain; **VB**, vaginal bleeding; **OR**, oophorectomy; **BA0**, a total hysterectomy with bilateral adnexectomy and an omentectomy; **CT**, chemotherapy; **RT**, radiotherapy; **SS, second surgery; IA**, ifosfamide + adriamycin; **DTIC**, dacarbazine; **PVB**, Cisplatin + Vincristine + Bleomycin; **IAP**, ifosfamide + adriamycin + Cisplatin; **AP**, adriamycin + Cisplatin; **VP-16**, etoposide; TP, paclitaxel + cisplatin

![**Kaplan-meier survival curves for the clinicopathologic factors of patients with ovarian fibrosarcoma**. **(A)**Survival curves for the OS and DFS rates associated with 31 patients diagnosed with ovarian fibrosarcoma as indicated. **(B)**Survival curves for OS and DFS rates in relation to various FIGO stages of ovarian fibrosarcoma as indicated. **(C)**Survival curves for OS and DFS rates in relation to the percentage of Ki-67-positive cells detected (\< 10% shown in red and ≥ 10% shown in blue). **(D)**Survival curves of OS and DFS rates associated with BAO/OR/CT/OR + RT/BAO+RT (shown in blue) vs. BAO + CT alone (shown in red).](1471-2407-10-585-1){#F1}

Pathologic Features
-------------------

The tumors detected ranged from 5.2 - 23 cm for the greatest diameter (average, 11.5). The specimens from the Medical College of Shantou University (n = 3) and the Cancer Center, Sun Yat-sen University (n = 5) were solid tumors, and a cut of the surface of the tumor revealed tan-yellow discoloration and partial necrosis. Microscopically, spindle-shaped cells were densely arranged in a whirling pattern, with myxoid stroma and hemorrhages observed in some areas. In general, the tumor cells contained elongated hyperchromatic nuclei, and in some areas, round or oval nuclei were observed. In all 31 cases, the mitotic value ranged from 1 - 25 mitoses per 10 high powered fields (HPFs) examined. For example, 3/31 (10%) cases had a mitotic count \< 4 per 10 HPFs, while for 18/31 (58%) cases the mitotic count was ≥ 4 and \< 10 per 10 HPFs, and for 10/31 (32%) cases the mitotic count was ≥ 10 per 10 HPFs. For a subset of cases, the Ki-67 (MIB-1) proliferation index values were also available, and included values of \< 10% for 5 cases, ≥ 10% and \< 50% for 9 cases, and ≥ 50% up to 85% for 5 cases. Tumor cells from a subset of cases were also associated with strong expression of vimentin (22/22, 100%) and an absence of CD117 expression (0%, 5/5). Additional immunohistochemical assays that were performed for a subset of the cases examined included detection of smooth muscle actin (SMA) (2/18, 11%), desmin (1/13, 8%), epithelial membrane antigen (EMA) (0/11, 0%), S-100 (1/19, 5%), CD99 (0/6, 0%), CD34 (1/5, 20%), α-inhibin (7/15, 47%), estrogen receptor (ER) (1/6, 17%), and progesterone receptor (PR) (1/6, 17%) (Table [1](#T1){ref-type="table"}).

Univariate and multivariate analysis
------------------------------------

Various clinicopathologic variables were also evaluated to identify potential prognostic factors for survival. Univariate analysis identified FIGO stage, Ki-67-positive cells, and therapy to be associated with the prognosis of patients with ovarian fibrosarcomas (*P*\< 0.05). The 2-year OS and DFS rates for FIGO stage Ia-Ic, or FIGO stage IIa-IIIc, were 77.1% and 36.2% (*P*= 0.014), and 68.4% and 22.9% (*P*= 0.003), respectively in each case (Figure [1B](#F1){ref-type="fig"}). When the 2-year OS rate was evaluated in relation to the percentage of Ki-67-positive cells, the survival of patients with \< 10% vs. ≥ 10% of Ki-67 positive cells was 100% and 27.2%, respectively (*P*= 0.042). Similarly, the 2-year DFS rate for the same categories of Ki-67 were 66.7% and 36.3%, respectively (*P*= 0.076) (Figure [1C](#F1){ref-type="fig"}). In terms of treatments received, the 2-year OS rate for patients receiving BAO, OR, or BAO + RT, was 27.9%, while patients receiving BAO + CT had a 2-year OS rate of 100% (*P*= 0.002). For the same categories of patient treatment, the 2-year DFS rates were 28.5% and 72.9%, respectively (*P*= 0.008) (Figure [1D](#F1){ref-type="fig"}). In contrast, patient age (2-year OS, *P*= 0.348; 2-year DFS *P*= 0.224), tumor size (2-year OS, *P*= 0.793; 2-year DFS, *P*= 0.666), and mitoses/10 HPFs (2-year OS, *P*= 0.426; 2-year DFS *P*= 0.830) were not found to be prognostic for survival (Table [2](#T2){ref-type="table"}).

###### 

The 2-year OS and DFS rates associated with ovarian fibrosarcoma patients and Cox proportional hazard regression analysis of patient survival based on clinical and pathologic factors

  Variables                    Case (%)    2 year\'s rate   2 year\'s rate   Cox (OS)    Cox (DFS)                                                                                                                                                          
  ---------------------------- ----------- ---------------- ---------------- ----------- ----------- ------- ----------- ---------------------- ----------- ----------------------- ----------- ---------------------- ----------- ------------------------ -----------
  **Age (years)**                                                                                                                                                                                                                                           
  \< 45                        15 (48.4)   66                                            60                                                                                                                                                                 
  ≥ 45                         16 (51.6)   45.4             0.879            0.348       27.8        1.476   0.224       1.731 (0.540-5.545)    0.356                                           1.882 (0.658-5.382)    0.238                                
  **FIGO stage**                                                                                                                                                                                                                                            
  I a - I c                    14 (45.2)   77.1                                          68.4                                                                                                                                                               
  II a - III c                 17 (54.8)   36.2             6.041            **0.014**   22.9        8.964   **0.003**   4.525 (1.210-16.916)   **0.025**   10.156 (2.021-51.023)   **0.005**   4.914 (1.538-15.704)   **0.007**   18.761 (1.674-210.288)   **0.017**
  **Largest diameter (cm)**                                                                                                                                                                                                                                 
  \< 10                        11 (45.8)   43.2                                          44.4                                                                                                                                                               
  ≥ 10                         13 (54.2)   54.7             0.069            0.793       38.9        0.187   0.666       0.844 (0.236-3.014)    0.794                                           1.302 (0.389-4.360)    0.669                                
  **Mitoses/10 HPFs**                                                                                                                                                                                                                                       
  \< 4                         22 (71.0)   49.7                                          48                                                                                                                                                                 
  ≥ 4                          9 (29.0)    70               0.632            0.426       41.7        0.046   0.83        0.545 (0.119-2.499)    0.435                                           1.132 (0.358-3.575)    0.833                                
  **Ki-67 (MIB-1)-positive**                                                                                                                                                                                                                                
  \< 10                        5 (26.3)    100                                           66.7                                                                                                                                                               
  ≥ 10                         14 (73.7)   27.2             4.148            **0.042**   36.3        3.138   0.076       51.792 (0.053-5058)    0.261                                           5.862 (0.668-51.416)   0.11                                 
  **Therapy**                                                                                                                                                                                                                                               
  BAO/OR/CT/BAO+RT/OR+RT       20 (64.5)   27.9                                          28.5                                                                                                                                                               
  BAO+CT                       11 (35.5)   100              9.462            **0.002**   72.9        6.97    **0.008**   0.070 (0.008-0.574)    **0.013**   0.029 (0.003-0.319)     **0.004**   0.197 (0.052-0.741)    0.016       0.071 (0.005-0.992)      **0.049**

**HR**, hazard ratio; **CI**, confidence interval; **OS**, overall survival; DFS, disease-free survival; **CS**, cytoreductive surgery; **OR**, oophorectomy; **CT**, chemotherapy; **RT**, radiotherapy; **BA0**, a total hysterectomy with bilateral adnexectomy and an omentectomy

A role for multimodal therapy in patient prognosis was also examined. Due to the limited numbers of patients included in this study, the available cases were divided into two groups: those receiving BAO, OR, CT, OR + RT, or BAO+RT therapy, and those receiving BAO+CT. For these groups, 12/20 (60%) patients vs 1/11 (9.1%) patient died of their disease within 5 years, respectively. Furthermore, patients in the former group were associated with a poorer prognosis and a 2-year OS rate of 27.9%, compared to those in the latter group that were associated with a 2-year OS rate of 100% \[HR, 0.07; 95% CI, 0.008-0.574; *P*= 0.013\] (Figure [1D](#F1){ref-type="fig"}).

Cox proportional hazard regression analysis of patient survival based on clinical and pathologic factors was also performed. Multivariate analysis identified FIGO stage (Ia- Ic vs. IIa- IIIc, Hazard Ratio (HR) = 0.231, 95% CI of ratio = \[0.072, 0.743\], *P*= 0.007) and treatment (BAO/OR/CT/OR + RT/BAO+RT vs. BAO+CT, HR = 6.516, 95% CI of ratio = \[1.974, 21.52\], *P*= 0.008) to be significant independent prognostic factors for survival. In contrast, patient age, tumor size, mitosis events per 10 HPFs, and percentage of Ki-67-positive cells present were not found to be significant independent prognostic factors for survival (Table [2](#T2){ref-type="table"}).

Discussion
==========

Ovarian fibrosarcoma is an extremely rare entity \[[@B1],[@B2],[@B11]\], and is considered to arise directly from stromal cells around the sex cord of ovarian follicles. However, the malignant transformation of a previous fibroma is also believed to be a potential origin of ovarian fibrosarcoma as well. These tumors can occur at any age, although they are mostly diagnosed in menopausal and postmenopausal women. Clinically, the presentation of this disease includes pelvic pain, abdominal enlargement, or awareness of an abdominal mass \[[@B1]-[@B3]\]. In addition, the majority of tumors exhibit areas of necrosis and haemorrhage, capsular disruption, as well as infiltrative margins that lead to adhesion of the tumor with other pelvic organs. For the 31 cases compared in this study, the median patient age was 49 years, and 19 patients presented at a hospital with abdominal pain, vaginal bleeding, or notable pelvic swelling.

Previous studies have reported a moderate to marked degree of pleomorphism to be associated with ovarian fibrosarcomas, with the number of mitotic figures observed ranging from 4-25 per 10 HPFs \[[@B1],[@B2],[@B12],[@B13]\]. For example, in an evaluation of 17 cases of malignant, as well as cellular, fibromatous tumors of the ovary, Prat and Scully \[[@B2]\] classified these cases into two categories, those with 1-3 mitotic figures per 10 HPFs, which were designated as cellular fibromas, vs. those with greater than 4 mitoses per 10 HPFs, which were designated as fibrosarcomas. Usually, these criteria would not present a problem. However, the results of a recent study by Irving et al. indicate that mitotic activity is not a unique criteria for malignancy. For example, cases of ovarian fibromatous tumors were found to be associated with a very high mitotic count, whereas blunt nuclei, which usually do not exhibit an aggressive course of disease, were diagnosed as \'mitotically active cellular fibromas\' instead of fibrosarcomas \[[@B14]\]. In our study, 18 cases were associated with a mitotic count ≥ 4 or \< 10, and 10 cases had a mitotic count ≥ 10. Only three cases had a mitotic count \< 4. However, in the latter cases, one patient developed a metastasis in the liver one year later, one patient died 4 months following the surgery, and one patient was tumor-free for 45 months.

In work by Tsuji et al. \[[@B3]\], the Ki-67 index values for fibrosarcomas were found to be higher than the Ki-67 values for fibromas. In doubtful cases, an assessment of the proliferative activity according to the MIB-1 labeling index was found to improve the accuracy of the diagnosis \[[@B3]\]. In the present study, there were three doubtful cases. However, when morphology, immunohistochemical results, and proliferative features were examined, a clear diagnosis of fibrosarcoma could be made. Furthermore, high levels of Ki67 (MIB-1) expression were consistent with a malignant diagnosis, despite a low visual mitotic rate that was also observed. However, when a multivariate analysis was performed, the presence of Ki-67-positive cells was not found to be a significant independent prognostic factor for survival.

The optimization of treatment strategies to improve patient outcome for patients diagnosed with an aggressive tumor such as ovarian fibrosarcoma, have not been identified. As a result, most patients experience a fatal outcome due to early metastasis via the bloodstream and tumor recurrences that usually occur within 2 years of diagnosis. Furthermore, there is no universally accepted treatment modality for ovarian fibrosarcoma as there is for epithelial ovarian cancers. For example, surgical resection for an ovarian fibrosarcoma can range from a simple adnexectomy, to a total hysterectomy with bilateral adnexectomy and an omentectomy. In many cases, post-surgical adjuvant chemotherapy or radiation is also required \[[@B15],[@B16]\]. After reviewing several studies, Miles et al. reported that surgery did not prevent the recurrence of this disease regardless of the extent of surgery, and adjuvant chemotherapy and radiation therapy did not influence patient survival \[[@B16]\]. Moreover, there are few reports to indicate that adjuvant chemotherapy may improve patient survival rates, although Huang et al. reported that the use of MAID (mesna, doxorubicin, ifosfamide, and DTIC) for the treatment of ovarian fibrosarcoma has shown potential for prolonging patient survival \[[@B4]\]. Moreover, Celyk et al. reported that a regimen of paclitaxel plus cisplatin can improve the prognosis for patients with advanced stage tumors in some cases \[[@B11]\]. In the present study, multimodal therapy was evaluated for its capacity to improve patient prognosis, and BAO surgery followed by chemotherapy was associated with the greatest improvement in prognosis.

Conclusion
==========

In conclusion, high rates of Ki-67-positive cells, representing a high proliferation rate, may contribute to the malignant characteristic associated with ovarian fibrosarcomas. However, this is in contrast with the low visual mitotic rate associated with these tumors. The results of the present study indicate that FIGO stage and treatment modality may represent prognostic factors for patient survival, and BAO followed by adjuvant chemotherapy is associated with an improved treatment outcome. In addition, although this study was retrospective in design, and included a limited number of patients, it is one of the largest series reported to date. As such, these results provide valuable insight into a challenging and rare disease, and contribute to the limited body of knowledge that is currently available for this aggressive tumor type.
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